Therapies for galactosemia: a patent landscape

David J Timson

doi:10.4155/ppa-2020-0004

Therapies for galactosemia: a patent landscape

David J Timson

Centre for Lifelong Health

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Pharmaceutical Patent Analyst
DOIs	https://doi.org/10.4155/ppa-2020-0004
Publication status	Published - 21 Apr 2020

Keywords

aldose reductase inhibitors
cataracts
galactose 1-phosphate uridylyl
transferase
GALT
inherited metabolic disease
leloir pathway
mRNA therapy
PI3K/Akt signalling
salubrinal
Type I galactosemia

Access to Document

10.4155/ppa-2020-0004

Therapies for galactosemia: a patent landscapeAccepted author manuscript, 156 KB

Cite this

@article{d5d473e11592493d9cc687abb56c97dd,

title = "Therapies for galactosemia: a patent landscape",

keywords = "aldose reductase inhibitors, cataracts, galactose 1-phosphate uridylyl, transferase, GALT, inherited metabolic disease, leloir pathway, mRNA therapy, PI3K/Akt signalling, salubrinal, Type I galactosemia",

author = "Timson, {David J}",

year = "2020",

month = apr,

day = "21",

doi = "10.4155/ppa-2020-0004",

language = "English",

journal = "Pharmaceutical Patent Analyst",

}

TY - JOUR

T1 - Therapies for galactosemia

T2 - a patent landscape

AU - Timson, David J

PY - 2020/4/21

Y1 - 2020/4/21

KW - aldose reductase inhibitors

KW - cataracts

KW - galactose 1-phosphate uridylyl

KW - transferase

KW - GALT

KW - inherited metabolic disease

KW - leloir pathway

KW - mRNA therapy

KW - PI3K/Akt signalling

KW - salubrinal

KW - Type I galactosemia

U2 - 10.4155/ppa-2020-0004

DO - 10.4155/ppa-2020-0004

M3 - Article

JO - Pharmaceutical Patent Analyst

JF - Pharmaceutical Patent Analyst

ER -